Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT2B7 | P16662 | 2/20 | 0.36 |
| ▸ | CETP | P11597 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.30 |
| ▸ | CDC25A | P30304 | 1/20 | 0.30 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10715339 | 1.00 | UGT2B7 (0.36) | UGT2B7CETPPTPN1CDC25ADUSP3 | |
| SCHEMBL10712409 | 1.00 | UGT2B7 (0.36) | UGT2B7CETPPTPN1CDC25ADUSP3 | |
| SCHEMBL14850614 | 1.00 | UGT2B7 (0.36) | UGT2B7CETPPTPN1CDC25ADUSP3 | |
| SCHEMBL813797 | 0.89 | UGT2B7 (0.37) | UGT2B7CETPPTPN1CDC25ADUSP3 | |
| SCHEMBL1149570 | 0.82 | UGT2B7 (0.38) | UGT2B7CETPPTPN1 | |
| SCHEMBL2707186 | 0.82 | UGT2B7 (0.51) | UGT2B7CETPPTPN1CDC25ADUSP3 | |
| SCHEMBL8202623 | 0.82 | UGT2B7 (0.35) | UGT2B7CETPCDC25A | |
| SCHEMBL28905336 | 0.81 | UGT2B7 (0.38) | UGT2B7CETPPTPN1 | |
| SCHEMBL2463622 | 0.80 | UGT2B7 (0.39) | UGT2B7CDC25A | |
| SCHEMBL2706966 | 0.79 | ALDH1A1 (0.42) | UGT2B7CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067644-B2 | Process for conducting an organic reaction in ionic liquids | THE PROCTER & GAMBLE COMPANY (US) | 2011-11-29 | — | — | US | claimed |
| US-20110152566-A1 | Process for Conducting an Organic Reaction in Ionic Liquids | THE PROCTER & GAMBLE COMPANY | 2011-06-23 | — | — | US | claimed |
| US-11965195-B2 | Enzyme mediated process | GIVAUDAN SA (CH) | 2024-04-23 | — | — | US | disclosed |
| US-20230009254-A1 | ENZYME MEDIATED PROCESS | GIVAUDAN SA (CH) | 2023-01-12 | — | — | US | disclosed |
| WO-2021110858-A1 | ENZYME MEDIATED PROCESS | GIVAUDAN SA (CH) | 2021-06-10 | — | — | WO | disclosed |
| EP-2747886-B1 | SELECTIVE HYDROGENATION OF ALDEHYDE WITH RU/BIDENTATE LIGANDS COMPLEXES | FIRMENICH & CIE (CH) | 2018-11-14 | — | — | EP | disclosed |
| EP-2970067-B1 | SELECTIVE HYDROGENATION OF ALDEHYDES WITH RU/BIDENTATE LIGANDS COMPLEXES | FIRMENICH & CIE (CH) | 2017-08-16 | — | — | EP | disclosed |
| US-9714263-B2 | Selective hydrogenation of aldehydes with Ru/bidentate ligands complexes | FIRMENICH SA (CH) | 2017-07-25 | — | — | US | disclosed |
| US-20160039853-A1 | SELECTIVE HYDROGENATION OF ALDEHYDES WITH RU/BIDENTATE LIGANDS COMPLEXES | FIRMENICH SA (CH) | 2016-02-11 | — | — | US | disclosed |
| EP-2970067-A1 | SELECTIVE HYDROGENATION OF ALDEHYDES WITH RU/BIDENTATE LIGANDS COMPLEXES | Firmenich SA (CH) | 2016-01-20 | — | — | EP | disclosed |
| US-9090534-B2 | Selective hydrogenation of aldehyde with ru/bidentate ligands complexes | FIREMENICH SA (CH) | 2015-07-28 | — | — | US | disclosed |
| WO-2008113545-A1 | NOVEL PROCESS FOR THE PREPARATION OF TIMBERONE | DSM IP ASSETS B.V. (NL) | 2008-09-25 | — | — | WO | disclosed |
| EP-0118809-B1 | COMPOSITION ESSENTIALLY CONSISTING OF TRANS-1-(2,6,6-TRIMETHYLCYCLOHEXYL)-HEXAN-3-OL, UTILIZATION OF SAME AND PROCESS FOR ITS PREPARATION; CYCLOALIPHATIC KETONE AND ALCOHOL INTERMEDIATES | FIRMENICH SA (CH) | 1988-05-11 | — | — | EP | disclosed |
| US-4711875-A | PERFUMES | FIRMENICH SA (CH) | 1987-12-08 | — | — | US | disclosed |
| US-4626381-A | ORGANOLEPTIC | FIRMENICH SA (CH) | 1986-12-02 | — | — | US | disclosed |
| US-4623750-A | PERFUMES | FIRMENICH SA (CH) | 1986-11-18 | — | — | US | disclosed |
| US-4588849-A | Process for the preparation of an isomeric mixture of 1-(2,6,6-trimethylcyclohexyl)-hexan-3-ol | FIRMENICH SA (CH) | 1986-05-13 | — | — | US | disclosed |
| EP-0118817-B1 | PROCESS FOR THE PREPARATION OF AN ISOMERIC COMPOSITION OF 1-(2,6,6-TRIMETHYLCYCLOHEXYL)-HEXAN-3-OL, USE OF THE OBTAINED COMPOSITION AND INTERMEDIATE CARBINOLS | FIRMENICH SA (CH) | 1986-04-02 | — | — | EP | disclosed |
| EP-0118817-A1 | Process for the preparation of an isomeric composition of 1-(2,6,6-trimethylcyclohexyl)-hexan-3-ol, use of the obtained composition and intermediate carbinols | FIRMENICH SA (CH) | 1984-09-19 | — | — | EP | disclosed |
| EP-0118809-A2 | Composition essentially consisting of trans-1-(2,6,6-trimethylcyclohexyl)-hexan-3-ol, utilization of same and process for its preparation; cycloaliphatic ketone and alcohol intermediates | FIRMENICH SA (CH) | 1984-09-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152566-A1 | Process for Conducting an Organic Reaction in Ionic Liquids | ACSL3, ACSL1, MCOLN1 | UGT2B7 3861/4885CETP 3528/4885PTPN1 4786/4885 |
| US-20160039853-A1 | SELECTIVE HYDROGENATION OF ALDEHYDES WITH RU/BIDENTATE LIGANDS COMPLEXES | ADH5, ADH1A, ADH1C | UGT2B7 2496/4885CETP 4014/4885PTPN1 4072/4885 |
| US-11965195-B2 | Enzyme mediated process | HPD, DNPH1, ESD | UGT2B7 279/4885CETP 1007/4885PTPN1 3632/4885 |
| US-20230009254-A1 | ENZYME MEDIATED PROCESS | HPD, DNPH1, ESD | UGT2B7 279/4885CETP 1007/4885PTPN1 3632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.